{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:55:40Z","timestamp":1761486940186},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,11,13]],"date-time":"2002-11-13T00:00:00Z","timestamp":1037145600000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>  <jats:italic>Objectives<\/jats:italic>: Preliminary reports have suggested that autologous stem\u2010cell transplantation (ASCT) is feasible in elderly patients with acute myeloid leukemia (AML). The objective of this study was to describe the disease characteristics and treatment results from a series of 22 elderly AML patients undergoing ASCT. <jats:italic>Methods<\/jats:italic>: The median age was 64\u2003yr (range 61\u201371). Twenty patients were in first complete remission (CR1), two in CR2, and all were in performance status 0\u20131. The median interval between CR achievement and ACST was 3\u2003months (range 2\u20135). In 20 cases peripheral blood stem cells were infused, in two bone marrow. <jats:italic>Results<\/jats:italic>: All patients had a successful engrafment. One patient (5%) died from transplant\u2010related complications. The median number of days to granulocytes &gt;\u200a500\u2003mm<jats:sup>\u22123<\/jats:sup> and platelets &gt;\u200a20\u2003000\u2003mm<jats:sup>\u22123<\/jats:sup> was 11(range 9\u201315) and 13 (range 9\u201320), respectively. Non\u2010hematologic toxicity included WHO grade III\u2010IV stomatitis in 32% patients and grade IV nausea and vomiting in one (4.5%). Seven patients had fever of unknown origin, while in 14 a documented infection was diagnosed. Median duration of hospitalization was 31\u2003d (range 16\u201360). <jats:italic>Conclusions<\/jats:italic>: After a median follow\u2010up of 12\u2003months from ASCT, nine patients are alive in continuous CR and 13 died from AML relapse. Median survival from diagnosis and disease\u2010free survival (DFS) was 19 and 14\u2003months, respectively. Our data show that ASCT with a standard conditioning regimen is feasible in AML patients aged more than 60\u2003yr. Toxicity and hemopoietic recovery do not substantially differ from those observed in young adults. DFS and overall survival (OS) duration are encouraging, but a longer follow up is needed on a larger series of patients.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.02806.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:29Z","timestamp":1047408809000},"page":"200-204","source":"Crossref","is-referenced-by-count":14,"title":["Autologous stem\u2010cell transplantation for patients with acute myeloid leukemia aged over 60\u2003yr"],"prefix":"10.1034","volume":"69","author":[{"given":"Felicetto","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carellajr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Mario","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11,13]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"5","article-title":"Estimate of overall treatment results in acute nonlymphocytic leukemia based on age specific rates of incidence and of complete remission","volume":"69","author":"Brincker H","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_5_3_2","first-page":"231","article-title":"De novo acute myeloid leukaemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Northern Region Haematology Group","volume":"9","author":"Taylor PR","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200201000-00005"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00122-0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809068573"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.695"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03043.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.9.3323"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(98)00191-X"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392301"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501263320403"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09214-3"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1073"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401445"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702736"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02265.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700604"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701804"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701272"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_5_22_2","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment.","author":"World Health Organization.","year":"1979"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1382.1382"},{"key":"e_1_2_5_24_2","first-page":"693","article-title":"BAVC regimen and autograft for acute myelogenous leukemia in second complete remission","volume":"18","author":"Meloni G","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200122"},{"key":"e_1_2_5_26_2","volume-title":"Guidelines for Cancer Cytogenetics, Supplement to: an International System for Human Cytogenetic Nomenclature.","author":"ISCN.","year":"1995"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057928"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1390.bloodjournal8841390"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_30_2","first-page":"S6","article-title":"Higher dose of peripheral blood stem cells is critical to improve the outcome of patients over 60 years with acute myelocytic leukemia","volume":"25","author":"Gorin NC","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_31_2","first-page":"814","article-title":"Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission","volume":"86","author":"Ferrara F","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02277.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402113"},{"key":"e_1_2_5_34_2","first-page":"531","article-title":"Current uses of monoclonal antibodies in the treatment of acute leukemia","volume":"27","author":"Ruffner KL","year":"2000","journal-title":"Semin Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02806.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.02806.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T03:37:50Z","timestamp":1692675470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.02806.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1034\/j.1600-0609.2002.02806.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.02806.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}